China Medical University Hospital

Industrial Technology Research Institute

Shine-on Biomedical Co., Ltd.

Shi-Wei Huang

Der-Yang Cho

Shao-Chih Chiu

Chih-Ming Pan

Mei-Chih Chen

Yeh Chen

Yu-Chuan Lin

Chia-Ing Jan

Yi-Wen Chen

Ching-Ran Lee

Wen-Tien Tsai

Che-Min Kung

Chao-Jung Chen

Kai-Wen Kan

Ming-You Shie

Po-Ren Hsueh

Tien Ni

Jia-Xin Yu

The present disclosure provides an anti-specific antibody and the nucleic acid encoding sequence thereof, and uses of the same. The anti-specific antibody of the present disclosure achieves the effect of treatinginfection and enhancing immune cells againstthrough various efficacy experiments.

Anti-specific antibody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides a fusion protein and the nucleic acid encoding sequence thereof, and uses of the same. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Fusion protein and nucleic acid encoding sequence thereof, and uses of the same

A linear driving module includes: a control circuit, a dimming module, and a low-dropout regulator. The control circuit generates switch signals in response to a change in a pulsed DC voltage. The dimming module receives the pulsed DC voltage. The dimming module includes dimming units. Light-emitting diode units in the dimming units are in a light-on state or a light-off state. The low-dropout regulator receives an input voltage from the dimming unit, and converts the input voltage into a regulated voltage. The input voltage varies with the number of light-emitting diode units in the light-on state. The input voltage is lower than the pulsed DC voltage, and the regulated voltage is lower than the input voltage.

Linear driving module

The present disclosure provides an anti-tumor antigen nanobody that specifically binds to a human leukocyte antigen-G. The present disclosure also provides the nucleic acid sequence of the anti-tumor antigen nanobody, use of the anti-tumor antigen nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of HLA-G.

Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 &#x3b5;. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 &#x3b5;.

Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 &#x3b5;. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same

The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

Growing community of inventors

Taichung, Taiwan

Shi-Wei Huang